Executive Summary
Across 40 filings from NASDAQ-100 related entities on May 12, 2026, Q1 2026 earnings dominate with robust revenue growth in aerospace/defense (Ducommun +9% YoY), HVAC (Madison +33.8% YoY), IT services (Intellicheck +13% YoY, Intelligent Protection +15.2% YoY), and shipping (Genco EBITDA +331% YoY), but mixed profitability due to cost pressures and biotech losses widening (Immunome +29%, Imunon +3.6%).
Margin expansions noted in 4/10 reporting companies (e.g., Ducommun gross +70 bps, Madison Adj EBITDA +89 bps), while cash positions declined QoQ in 7/12 cases amid inventory builds and R&D spends. Forward-looking catalysts include Madison FY2026 guidance ($3.75-3.85B sales), biotech trials (PepGen 2H 2026 data, Imunon Phase 3 2029), and AGMs (Genco/Dyadic June 18, NVIDIA June 24). Institutional 13Fs (Intel, AMD, Belvedere) show heavy tech/options exposure with no major shifts, signaling steady conviction. Shipping M&A battle (Diana 14.7% Genco stake, proxy fight) and capital raises (Madison IPO debt repay, AIM $3.6M warrants) highlight deleveraging trends. Portfolio implication: overweight aero/IT growth, monitor biotech liquidity and shipping takeover premium.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · 13F · 10-Q · DEF 14A · Schedule 13D · DEFA14A · Schedule 13G
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from May 11, 2026.
Investment Signals (12)
- Ducommun Inc ↓ (BULLISH)▲
Record Q1 revenue +9% YoY to $209M, gross margins +70 bps to 26.9%, adj EBITDA +19% to $35.4M, Electronic Systems margin +350 bps to 19.5%
- Madison Air Solutions ↓ (BULLISH)▲
Q1 sales +33.8% YoY to $923.7M (organic +11.7%), Adj EBITDA +38.7% to $233.4M (+89 bps margin), FY2026 guidance $3.75-3.85B sales/$1.02-1.065B EBITDA post-IPO deleveraging to 3.0x
- Intellicheck Inc ↓ (BULLISH)▲
Record Q1 revenue +13% YoY to $5.5M (SaaS +13%), swung to net income $636k from $318k loss, gross margin +130 bps to 91%, Adj EBITDA $935k from loss, cash +$0.4M to $10.1M no debt
- Genco Shipping ↓ (BULLISH)▲
Q1 net income $9.3M from $11.9M loss, EBITDA +331% YoY to $34.2M (Adj +357% to $36.2M), TCE +63% to $19.3k, fleet utilization +120 bps to 99.2% amid takeover defense
- OptimumBank Holdings ↓ (BULLISH)▲
Q1 net income +20.5% YoY to $4.7M (EPS $0.39 vs $0.33), NII +39.9% to $13.2M, assets +14.1% QoQ to $1.27B, loans/deposits +13.8/17.3%
- Immunome Inc ↓ (BULLISH)▲
NDA submitted April 2026 for varegacestat (Phase 3 HR=0.16, 56% ORR), cash $583M into 2028 despite Q1 loss widening to $53.8M, ASCO 2026 oral data
- AIM ImmunoTech ↓ (BULLISH)▲
Closed $3.6M warrant exercise (7.5M shares at $0.48), issued new warrants for potential upside, positive capital inflow
- NVIDIA Corp ↓ (BULLISH)▲
FY2026 revenue +65% YoY to $215.9B, op income +60% to $130.4B, EPS +67% to $4.90, Compute & Networking +67% to $193.5B despite gross margin -3.9 pts
- Intelligent Protection Mgmt (BULLISH)▲
Q1 revenue +15.2% YoY to $6.4M (managed IT +19%, procurement +78%), Adj EBITDA improved 65% to -$168k loss, no long-term debt, assets +13.4% QoQ
- PepGen Inc ↓ (MIXED BULLISH)▲
Q1 net loss improved 41% YoY to $17.8M (R&D -49% to $13M), cash $132M into 2H 2027, FREEDOM2 positive data 2H 2026 despite partial hold
- Imunon Inc ↓ (BULLISH)▲
Phase 2 OS +14.7 months (45.1 vs 30.4), Phase 3 enrollment ahead to Q1 2029, FDA-aligned BLA despite Q1 loss +3.6%
- Muncy Columbia Financial ↓ (BULLISH)▲
Declared dividend + authorized new treasury repurchase program, signaling shareholder returns
Risk Flags (10)
- Imunon Inc↓ [HIGH RISK]▼
Q1 net loss +3.6% YoY to $4.2M, cash -45% QoQ to $4.8M ($4M burn +40% YoY), liquidity pressures with plans for funding/partnerships
- Immunome Inc↓ [HIGH RISK]▼
Q1 net loss +29% to $53.8M (op ex +25% to $59.3M, R&D +26%), no collaboration revenue (100% down), cash -11% QoQ to $583M
- PepGen Inc↓ [MEDIUM RISK]▼
Cash -30% QoQ to $42M, FDA partial hold on FREEDOM2 despite positive data, total equity -9% to $134M
- Intelligent Protection Mgmt [MEDIUM RISK]▼
Swung to Q1 net loss $660k from $809k income (no tax benefit), professional svcs -33.5% YoY, subscription -9.7%
- Madison Air Solutions↓ [MEDIUM RISK]▼
GAAP net income -6.9% YoY to $43M, Residential organic -1.9%, FCF flat $50.4M, pre-IPO leverage dynamics
- Cottonwood Communities↓ [HIGH RISK]▼
Q1 op loss $7.2M from $0.9M income (op ex +37.7% to $54.7M), assets -1.3% QoQ to $2.16B
- Ducommun Inc↓ [MEDIUM RISK]▼
Industrial end-markets -decline, Structural margin -50 bps to 11.4%, future commercial aero destocking headwinds
- Richmond Mutual Bancorp↓ [MEDIUM RISK]▼
Assets -0.4% QoQ, loans -0.2% QoQ, comprehensive income -90% to $0.3M on $2.5M unrealized sec loss, non-int ex +3.9%
- Muzero Acquisition↓ [LOW RISK]▼
Shareholders' deficit widened to -$6M from -$25k on Class A accretion, op loss $205k despite $922k net income from trust interest
- OptimumBank↓ [MEDIUM RISK]▼
Non-int ex +42.2% YoY to $8M, provision $0.8M vs reversal prior, net cash investing outflow $134M on loan growth
Opportunities (10)
- Ducommun Inc↓ (OPPORTUNITY)◆
Commercial aero +18% YoY, defense gains (F-35/F-15), SG&A -lower 8.4% rev (vs 11.6%), capex -39% YoY signaling efficiency
- Madison Air Solutions↓ (OPPORTUNITY)◆
Data center cooling >50% of Commercial organic +17.2%, post-IPO net leverage 3.0x down 0.2x, FY guidance intact
- Intellicheck↓ (OPPORTUNITY)◆
SaaS dominance 100% rev, op ex -5.4% YoY, deferred rev +76% QoQ to $2.9M signaling backlog
- Genco Shipping/Diana Shipping↓ (OPPORTUNITY)◆
Activist 14.7% stake, $23.50/share tender (31% premium, 1.0x NAV), proxy fight June 18 AGM, potential re-rating to $26.50+ analyst NAV
- Immunome Inc↓ (OPPORTUNITY)◆
Phase 3 success + ASCO oral, ADC pipeline advancing (IM-1021 Ph1, IM-1617 IND), cash runway to 2028 undervalued vs peers
- Imunon Inc↓ (OPPORTUNITY)◆
OVATION 3 Phase 3 ahead of plan (first dose Q3 2025), OS data beats prior, conf call May 12 11am ET for details
- NVIDIA↓ (OPPORTUNITY)◆
Compute growth +67% on AI tailwinds, AGM June 24 vote on comp/auditors, potential for continued EPS beats
- AIM ImmunoTech↓ (OPPORTUNITY)◆
Warrant inducement unlocks $3.6M cash at discount, new warrants at $0.60 exercisable post-approval
- Dyadic Int↓ (OPPORTUNITY)◆
Discretionary reverse split auth + comp vote at June 18 virtual AGM, insider ownership 20.9% alignment
- Murphy USA↓ (OPPORTUNITY)◆
$500M notes pricing for 2027 redemption + RCF repay, deleveraging into 2034 maturity
Sector Themes (6)
- Aerospace/Defense Growth (BULLISH IMPLICATION)◆
Ducommun +9% rev YoY (commercial +18%, defense missiles/F-35), margins mixed (+70 bps gross but Structural -50 bps), signals re-acceleration post-destocking
- Biotech Cash Burn & Catalysts◆
4/5 biotechs (Imunon/Immunome/PepGen/AIM) show widening losses (avg +25% YoY) & cash -20-45% QoQ, but trial catalysts (NDA, Ph3 data 2H26/2029, OS beats) offer binary upside [MIXED, VOLATILE]
- IT Services Resilience (BULLISH TURNAROUND)◆
Intellicheck/Intelligent Protection avg +14% rev YoY, profitability swings (Intellicheck to profit, IPM to loss), SaaS/managed IT strength, no debt
- Shipping M&A Drama (HIGH ALPHA OPPORTUNITY)◆
Genco Q1 turnaround (EBITDA +331%) vs Diana 14.7% stake/hostile bid, proxy fights June 18, rights plan; undervaluation vs NAV
- Institutional Tech Conviction (BULLISH STEADY)◆
13Fs (Belvedere/Azimuth/Community/Ilmarinen) heavy Apple/NVDA/MSFT/Broadcom/AMD calls/options (e.g., Belvedere $14.8B Eversource puts but tech calls $1.2B+), no major sells
- Capital Deleveraging (DEFENSIVE)◆
Madison IPO repays $2.66B debt, Murphy $500M notes redeem 2027s, AIM warrant cash; 3/5 cases lower leverage post-Q1
Watch List (8)
-
Proxy fight/AGM June 18, tender at $23.50/share, board nominees vote, potential takeover escalation or rights plan trigger [June 18, 2026]
-
Virtual AGM June 24, vote on 10 directors/exec comp/PwC ratification vs 4 stockholder proposals [June 24, 2026]
-
Virtual AGM June 18, reverse split auth, auditor/comp votes, 20.9% insider ownership [June 18, 2026]
-
ASCO 2026 oral on Phase 3 varegacestat data, NDA FDA review timeline [ASCO 2026]
-
FREEDOM2 10mg/kg data 2H 2026, FDA hold resolution, OLE enrollment [2H 2026]
-
Phase 3 OVATION 3 enrollment (complete Q1 2029), May 12 conf call recap [Q1 2029; call May 12, 2026]
-
Post-IPO execution on FY2026 guidance $3.75-3.85B sales, data center growth [Ongoing 2026]
-
Post-AGM May 12 director elections/approvals, FY2026 auditor watch [Post-May 12, 2026]
Filing Analyses
(40)
12-05-2026
Ducommun Incorporated reported record Q1 2026 net revenue of $209.0 million, up 9% YoY from $192.5 million, driven by 18% growth in commercial aerospace and gains in defense including missiles and fixed-wing platforms like F-35 and F-15. Gross margins expanded 70 bps to 26.9%, net income surged 607% to $9.9 million, and adjusted EBITDA rose 19% to $35.4 million (16.9% of revenue); however, industrial end-use markets declined $1.4 million, Structural Systems operating margin dipped slightly to 11.4% from 11.9%, and future destocking headwinds are expected in commercial aerospace.
- · Electronic Systems operating income $22.9M (19.5% margin) vs $17.5M (16.0%) YoY.
- · Structural Systems operating income $10.4M, up $0.5M YoY but margin down 50 bps.
- · CG&A expenses $17.6M (8.4% of revenue) vs $22.4M (11.6%) YoY, due to lower stock-based compensation.
- · Interest expense $4.0M vs $3.3M YoY.
- · Cash and cash equivalents declined to $39.1M from $45.3M at Dec 31, 2025.
12-05-2026
Intel Corp filed Form 13F-HR on May 12, 2026, disclosing institutional equity holdings as of March 31, 2026, with a total portfolio value of $470012761000. Key holdings include two positions in Joby Aviation Inc. Common stock valued at $10637988000 and $20132874000, and Mobileye Global Inc. Class A with 50000000 shares valued at $343500000000. The filing lists three managing entities with no period-over-period comparisons provided.
- · Three investment managers disclosed
- · CUSIP for Joby Aviation Inc.: G65163100
- · CUSIP for Mobileye Global Inc. Class A: 60741F104
12-05-2026
Ducommun Inc reported robust Q1 2026 financial results with net revenues increasing 8.6% YoY to $209,022 from $192,481, gross profit up 11.5% to $56,233, and operating income surging 216% to $15,720 driven by a 10% reduction in SG&A expenses to $40,513 and absence of restructuring charges. Net income rose sharply 607% to $9,916 ($0.66 basic EPS) from $1,402 ($0.09), while cash flow from operations improved to $11,239 from $771. However, cash and equivalents declined 14% QoQ to $39,103 from $45,289, reflecting increases in accounts receivable and inventories alongside financing outflows.
- · Prior period financials for three months ended March 29, 2025 are as restated.
- · Weighted-average basic shares outstanding increased to 15,044 from 14,856 YoY.
- · Capex (purchases of property and equipment) decreased to $2,936 from $4,815 YoY.
12-05-2026
Madison Air Solutions Corp reported Q1 2026 net sales of $923.7 million, up 33.8% YoY (12.5% pro forma), with strong segment growth in Residential (+59.8%) and Commercial (+23.5%), while Adjusted EBITDA increased 38.7% to $233.4 million (margin up 89 bps to 25.3%). However, GAAP net income fell 6.9% to $43.0 million, free cash flow was flat at $50.4 million, and organic Residential sales declined 1.9% with volume declines in some Commercial areas like air handling. Post-quarter, the company completed its IPO raising $2,584.2 million in net proceeds to repay $2,661.2 million in debt, and issued FY2026 guidance of $3,750-$3,850 million net sales and $1,020-$1,065 million Adjusted EBITDA.
- · Commercial organic growth of 17.2% driven over half by data center cooling, partially offset by declines in air handling and commercial dehumidification.
- · Residential Adjusted EBITDA decreased $1.4 million after AprilAire acquisition due to volume declines in professional distribution channels.
- · Pre-IPO net leverage down ~0.2x from year-end; post-IPO adjusted net leverage 3.0x.
- · FY2026 guidance: Net sales $3,750-$3,850M; Adjusted EBITDA $1,020-$1,065M.
- · Backlog up 115.5% YoY and orders up 29.1% on combined basis.
12-05-2026
Madison Air Solutions Corp reported net sales of $923.7M for the three months ended March 31, 2026, up 33.8% YoY from $690.4M, primarily driven by acquisitions (21.2% impact) with overall organic growth slowing to 11.7% from 19.2%; Commercial organic growth was solid at 17.2% (down from 29.5%) while Residential organic declined 1.9% (vs -1.0% prior). Gross profit margin improved to 37.2% and adjusted net income rose to $92.5M from $70.0M, but reported net income dipped to $43.0M from $46.2M and FCF remained flat at $50.4M.
- · Net cash flows used in investing activities Q1 2026: $(8.1)M vs $4.5M provided in Q1 2025
- · Total net change in cash and cash equivalents Q1 2026: $20.2M vs $75.4M in Q1 2025
- · Pro Forma net sales three months ended March 31, 2025: $130.5M with Adjusted EBITDA margin of 25.7%
12-05-2026
Imunon, Inc. reported a net loss of $4.2M for Q1 2026, widening 3.6% YoY from $4.1M, driven by higher R&D expenses up 7.9% while G&A remained flat; loss per share improved to $(0.84) from $(3.15) due to share dilution. Cash and equivalents fell 45% QoQ to $4.8M from $8.8M amid $4.0M operating cash burn (up 40% YoY), though up from $2.9M at Q1 2025 end. Total assets declined to $8.0M from $12.3M, with plans to cut spending and seek funding signaling liquidity pressures.
- · Investment income increased to $57,530 from $42,804 YoY.
- · Operating lease right-of-use assets at $887,892 as of March 31, 2026.
- · Plans include reducing expenditures, pursuing equity/debt funding, partnerships, and out-licensing drug candidates.
- · No purchases of property and equipment in Q1 2026 vs $259,652 in Q1 2025.
12-05-2026
Muzero Acquisition Corp reported net income of $921,491 for the three months ended March 31, 2026, driven by $1,126,721 in interest income primarily from the Trust Account following its IPO, which funded $202,374,142 in investments held in Trust. However, the company recorded an operating loss of $205,230, and shareholders' deficit widened to $(6,008,384) from $(24,541) due to accretion of Class A shares to redemption value. Total assets grew significantly to $203,574,958 from $198,950, reflecting IPO proceeds, while cash and equivalents increased to $934,577 from $69.
- · Promissory Note – related party repaid to $0 from $145,000.
- · Advances from related party: $9,450 as of March 31, 2026.
- · Basic and diluted net income per share: $0.05 for both Class A redeemable and Class B non-redeemable ordinary shares.
- · Net cash used in operating activities: $(370,758).
- · Non-cash: Offering costs included in accrued offering costs $75,000; Deferred Fee payable $7,043,750.
12-05-2026
Immunome submitted an NDA to the FDA in April 2026 for varegacestat in desmoid tumors, following positive Phase 3 RINGSIDE data showing an 84% reduction in progression risk (HR=0.16), 56% ORR vs. 9% placebo, and -83% median tumor volume change vs. +11%; detailed data selected for ASCO 2026 oral presentation. The company advanced its ADC pipeline with ongoing Phase 1 for IM-1021, IND clearance for IM-1617, and plans for IM-3050 trial. Q1 2026 financials showed a net loss widening to $53.8M from $41.6M YoY, driven by R&D expenses rising to $46.4M (up from $36.9M) and G&A to $13.0M (up from $10.7M), with cash declining to $582.7M (sufficient into 2028).
- · Total assets $619.8M as of March 31, 2026 (down from $683.2M Dec 31, 2025)
- · Total operating expenses $59.3M Q1 2026 (up from $47.6M Q1 2025)
- · Interest income $5.5M Q1 2026 (up from $3.0M Q1 2025)
- · Net loss per share $0.48 Q1 2026 (improved from $0.52 Q1 2025)
- · Plans MAA submission to EMA for varegacestat by end 2026; Phase 1 IM-1617 initiation Q2 2026; INDs for IM-1340 mid-2026, IM-1335 late 2026
12-05-2026
Intelligent Protection Management Corp. (IPM) reported Q1 2026 total revenue of $6,354,751, up 15.2% YoY from $5,518,038, driven by 19% growth in core managed IT services to $3.4 million and 78.4% increase in procurement revenue to $1.7 million. However, professional services revenue declined 33.5% to $483,000 and subscription revenue fell 9.7% to $254,000, while net loss widened to $(660,214) from net income of $808,530 due to the absence of a prior-year $2.1 million tax benefit. Loss from operations improved 42.4% to $(768,182), and Adjusted EBITDA rose 65.3% to $(167,519).
- · Cash and cash equivalents totaled $8.1 million at March 31, 2026, including $1.0 million restricted cash, with no long-term debt.
- · Deferred revenue was $4,652,125 at March 31, 2026.
- · Total assets increased to $29,532,933 at March 31, 2026 from $26,040,517 at December 31, 2025.
- · 50,000 shares repurchased for $83,491; repurchase plan fully utilized as of March 31, 2026.
- · Conference call held May 12, 2026 at 4:30 p.m. ET.
12-05-2026
Napean Trading & Investment Co (Singapore) PTE Ltd filed Form 13F-HR on May 12, 2026, disclosing institutional equity holdings as of March 31, 2026, with a total portfolio market value of $232,963,608 across 16 positions, all held with sole voting and disposition power. Largest holdings include CUSIP 639193101 (CL A) at $77,775,163 (5,874,257 shares) and CUSIP 770700102 (COM CL A) at $72,751,279 (1,049,802 shares). No prior period data is available for comparison.
- · Filing period end date: March 31, 2026
- · All 16 positions reported as SH SOLE with 0 shared voting or disposition power
- · Smallest holding: CUSIP 16935C109 at $222,475 (11,878 shares)
12-05-2026
PepGen Inc. reported a Q1 2026 net loss of $17,763 thousand, an improvement of 41.2% YoY from $30,202 thousand, primarily due to a 48.7% reduction in research and development expenses to $13,004 thousand while general and administrative expenses remained flat at approximately $5,938 thousand. However, cash and cash equivalents declined 30.3% QoQ to $42,150 thousand from $60,514 thousand, and total stockholders' equity decreased to $133,980 thousand from $147,444 thousand. Net cash used in operating activities improved to $18,426 thousand from $22,930 thousand YoY, but overall cash position (including equivalents and restricted) fell to $43,698 thousand.
- · Interest income increased to $1,250 thousand in Q1 2026 from $1,122 thousand YoY.
- · Issuance of common stock from At-the-Market Sales Agreement generated $1,507 thousand net proceeds in Q1 2026.
- · Property and equipment, net declined to $1,565 thousand from $1,903 thousand QoQ.
12-05-2026
Intellicheck reported record Q1 2026 total revenue of $5,524,000, up 13% YoY from $4,894,000, driven by SaaS revenue growth of 13% to $5,514,000. Net income improved to $636,000 ($0.03 EPS) from a $318,000 loss ($0.02 EPS), with Adjusted EBITDA reaching a record $935,000 versus a $17,000 loss, gross margin expanding to 91.0% from 89.7%, and operating expenses declining 5.4% to $4,483,000. Cash balance grew to $10,062,000 with no debt, though cash from operations was $445,000 versus $750,000 YoY.
- · Accounts receivable increased to $5,740,000 as of March 31, 2026 from $3,365,000 at December 31, 2025.
- · Deferred revenue rose to $2,922,000 from $1,661,000 QoQ.
- · Total assets grew to $27,109,000 from $24,481,000 QoQ.
- · Earnings conference call held May 12, 2026 at 4:30 p.m. ET.
12-05-2026
PepGen reported Q1 2026 net loss of $17.8 million, improved from $30.2 million YoY, driven by R&D expenses declining 49% to $13.0 million while G&A remained flat at $5.9 million, with cash of $132.3 million sufficient to fund operations into 2H 2027. FREEDOM2-DM1 trial showed favorable safety, splicing, and vHOT data from the 5 mg/kg cohort, with the 10 mg/kg cohort fully enrolled and data expected in 2H 2026. However, the FDA imposed a partial clinical hold on FREEDOM2 related to preclinical studies, though study timing remains unaffected.
- · FDA granted PGN-EDODM1 Orphan Drug and Fast Track Designations for DM1.
- · 6 patients from FREEDOM2 enrolled in OLE at 5 mg/kg with no discontinuations.
- · Regulatory clearance received to initiate FREEDOM2 in South Korea, Australia, and New Zealand; sites active in Canada, UK, and South Korea.
- · Net loss per share $ (0.26) Q1 2026 vs $ (0.92) Q1 2025.
12-05-2026
Immunome Inc. reported no collaboration revenue for Q1 2026, down 100% YoY from $2,926, while operating expenses increased 25% YoY to $59,331 driven by higher R&D (+26% to $46,381) and G&A (+21% to $12,950), resulting in a net loss of $53,839 (29% larger than $41,640 in Q1 2025). Cash and cash equivalents declined 11% QoQ to $582,693 from $653,482, with net cash used in operations worsening to $58,638 from $53,055 YoY. Interest income improved 83% YoY to $5,492, but overall cash position decreased by $70,789 during the quarter.
- · In-process R&D asset purchases: $9,014 in Q1 2026 (up from $6,246 YoY)
- · Property and equipment purchases: $3,002 in Q1 2026 (down slightly from $3,665 YoY)
- · Share-based compensation expense: $7,953 in Q1 2026 (up from $5,703 YoY)
- · EPS basic and diluted: $(0.48) in Q1 2026 (improved from $(0.52) YoY)
12-05-2026
Belvedere Trading LLC reported 731 equity positions totaling $84,443,433,143 as of March 31, 2026, in its quarterly 13F-HR filing submitted on May 12, 2026. The portfolio heavily features sole discretionary options trading, with the largest position being $14,782,857,938 in put options on Eversource Energy (2,222,000 shares equivalent), followed by $3,894,496,062 in call options on the same stock. Other major holdings include call options on Apple Inc ($530,522,616), Broadcom Inc ($346,465,494), and AMD ($361,922,313), alongside exposures to leveraged ETFs, commodity trusts like abrdn metals ETFs, and tech/growth names.
- · All positions held with sole voting and disposition power
- · Business address: 10 S. Riverside Plaza, Suite 2100, Chicago, IL 60606
- · Heavy concentration in leveraged/inverse ETFs from Direxion and T-Rex, commodity physical trusts, and single-stock options on tech/semiconductors
12-05-2026
For the three months ended March 31, 2026, Intelligent Protection Management Corp. (IPM) reported total revenue of $6,354,751, up 15.2% YoY from $5,518,038, driven by 78.4% growth in procurement revenue to $1,696,901 and 10.2% increase in managed IT revenue to $3,920,494. However, professional services revenue declined 33.5% YoY to $483,300, subscription revenue fell 9.7% to $254,056, and the company swung to a net loss of $660,214 from net income of $808,530 in Q1 2025 amid higher costs. Balance sheet showed total assets up 13.4% QoQ to $29,532,933, but stockholders' equity decreased 4.0% to $17,465,779 due to the loss and common stock repurchases.
- · Cash and cash equivalents decreased slightly QoQ to $5,675,238 from $5,597,014.
- · Accounts receivable increased QoQ to $2,157,952 from $1,599,725.
- · Deferred revenue up QoQ to $4,652,125 from $3,878,114.
- · Litigation expenses of $101,609 related to Cisco ManyCam Litigation in Q1 2026.
- · Net cash used in operating activities $195,712 in Q1 2026 vs provided $1,744,783 in Q1 2025.
- · Common stock repurchases of 50,000 shares for $83,491 in Q1 2026.
12-05-2026
Intellicheck, Inc. reported Q1 2026 revenues of $5.5M, up 13% YoY from $4.9M, driven by SaaS growth of 13% to $5.5M, achieving net income of $636k versus a $318k loss in Q1 2025 and positive operating income of $542k. However, operating cash flow declined 41% YoY to $445k from $750k, with accounts receivable increasing $2.4M due to timing of collections, and total operating expenses decreased only modestly by 5% to $4.5M. Cash and equivalents rose to $10.1M as of March 31, 2026, up from $9.7M at year-end 2025.
- · Accounts receivable increased $2.4M QoQ to $5.7M, indicating potential collection delays.
- · Deferred revenue rose $1.3M QoQ to $2.9M.
- · No Level 2 or Level 3 fair value assets or liabilities.
- · Weighted average basic shares: 20,236,880 for Q1 2026 vs 19,816,043 for Q1 2025.
12-05-2026
NVIDIA's DEF 14A proxy statement for the June 24, 2026 virtual Annual Meeting of Stockholders seeks election of ten directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal 2027, and addresses four stockholder proposals. Fiscal 2026 results showed revenue up 65% YoY to $215.9 billion, operating income up 60% YoY to $130.4 billion, and diluted EPS up 67% YoY to $4.90; however, gross margin declined 3.9 points YoY to 71.1%. Compute & Networking revenue grew 67% YoY to $193.5 billion while Graphics revenue increased 57% YoY to $22.5 billion.
- · Annual Meeting record date: April 27, 2026
- · Fiscal 2026 ended January 25, 2026
- · Board recommends FOR election of ten directors, FOR advisory approval of executive compensation, FOR ratification of PwC, and AGAINST four stockholder proposals
12-05-2026
AIM ImmunoTech Inc. closed a warrant exercise inducement transaction on May 8, 2026, receiving aggregate gross proceeds of approximately $3.6 million from the cash exercise of 7,451,920 shares of existing warrants (Classes A-F) at a reduced price of $0.48 per share. In exchange, the company issued Inducement Warrants (Class H) to purchase up to 14,903,840 shares at $0.60 per share, exercisable after stockholder approval for five years. Placement agent Ladenburg Thalmann & Co. Inc. received cash fees and expenses totaling approximately $361,000 and Placement Agent Warrants for up to 6% of the exercised shares.
- · Inducement Letter dated May 7, 2026; transaction closed May 8, 2026; filing dated May 12, 2026.
- · Existing warrants originally issued: Class A/B on May 31, 2024; Class C/D on September 30, 2024; Class E/F on July 31, 2025.
- · Placement Agent Warrants exercisable at $0.60 (125% of reduced exercise price), five-year term, with piggyback registration rights.
- · Securities issued under Section 4(a)(2) exemption; not registered under Securities Act.
12-05-2026
Madison International Realty Holdings, LLC filed a 13F-HR for the period ending March 31, 2026, disclosing that it fully sold out of all its 13F advised securities during Q1 2026, resulting in zero holdings. The filing was required due to meeting the 13F reporting threshold in 2025, in accordance with regulations. No prior period holdings are detailed, but the complete liquidation represents a 100% reduction to zero.
- · Filed as of date: May 12, 2026
- · Conformed period of report: March 31, 2026
- · Business address: 300 Park Avenue, 3rd Floor, New York, NY 10022
12-05-2026
Diana Shipping Inc., through its wholly-owned subsidiary Dragon Merger Sub Inc., reports beneficial ownership of 6,413,151 shares (14.7%) of Genco Shipping & Trading Ltd's common stock as of May 6, 2026, amid an ongoing cash tender offer to acquire all outstanding shares at $23.50 per share, representing a 31% premium to the undisturbed share price and 1.0x NAV. The filing amends the prior Schedule TO and announces a campaign website (www.CashforGenco.com) criticizing Genco's board for refusing to engage on the offer and exhibiting entrenchment, while launching a proxy fight to elect six independent director nominees at Genco's June 18, 2026 annual meeting. No tender acceptance updates or changes in ownership are reported beyond the stated holdings.
- · Tender offer documents originally filed May 4, 2026; this is Amendment No. 2 filed May 12, 2026.
- · Genco's 2026 Annual Meeting of Shareholders scheduled for June 18, 2026.
- · Diana Shipping Inc. owns approximately 14.7% of Genco's outstanding shares.
- · All reported shares owned by Diana Shipping Inc.; Dragon Merger Sub Inc. has sole dispositive power over 6,413,151 shares and no voting power.
12-05-2026
Richmond Mutual Bancorporation, Inc. (RMBI) reported net income of $2,785,291 for the three months ended March 31, 2026, a 41.5% YoY increase from $1,968,310, with net interest income rising 11.6% YoY to $11,446,413 due to lower interest expense on deposits and borrowings. However, total assets declined 0.4% QoQ to $1,519,216,384 from $1,525,790,540, net loans decreased 0.2% QoQ to $1,174,121,856, non-interest expenses rose 3.9% YoY to $8,703,425, and comprehensive income dropped sharply to $319,019 from $3,244,492 due to a $2,466,272 unrealized loss on available-for-sale securities.
- · Provision for credit losses decreased to $693,094 from $731,095 YoY.
- · Basic EPS increased to $0.29 from $0.20 YoY.
- · Common stock dividends declared at $0.15 per share, totaling $1,464,950.
- · Net cash provided by operating activities rose to $2,785,570 from $2,180,680 YoY.
12-05-2026
Murphy USA Inc. priced a previously announced private offering of $500 million aggregate principal amount of 5.875% senior notes due 2034 issued by its wholly owned subsidiary, Murphy Oil USA, Inc., with guarantees from Murphy USA and certain domestic subsidiaries. The notes are issued at 100.000% and the offering is expected to close on May 27, 2026, subject to customary conditions. The unregistered notes will be offered only to qualified institutional buyers under Rule 144A and certain non-U.S. persons under Regulation S.
- · Notes guaranteed on a senior unsecured basis by Murphy USA and certain domestic subsidiaries.
- · Notes will not be registered under the Securities Act of 1933 or any state securities laws.
12-05-2026
Atmus Filtration Technologies Inc. held its Annual Meeting of Stockholders on May 12, 2026, electing Stephanie J. Disher, Diego Donoso, Heath Sharp, and Stuart A. Taylor II to its Board of Directors for three-year terms. Stockholders approved the advisory vote on executive compensation and ratified PricewaterhouseCoopers LLC as the independent auditor for the fiscal year ending December 31, 2026, with all proposals passing by overwhelming majorities exceeding 95% in favor where broker non-votes applied. Of 81,672,428 shares eligible to vote as of the March 23, 2026 record date, 75,920,780 shares were present or represented by proxy.
- · Proposal 1 Director Election - Stephanie J. Disher: For 71,811,918; Against 484,851; Abstain 13,451
- · Proposal 1 Director Election - Diego Donoso: For 70,727,528; Against 1,457,764; Abstain 124,928
- · Proposal 1 Director Election - Heath Sharp: For 71,622,151; Against 673,856; Abstain 14,213
- · Proposal 1 Director Election - Stuart A. Taylor II: For 71,077,282; Against 1,219,802; Abstain 13,136
- · Proposal 2 Advisory Vote on Executive Compensation: For 70,927,113; Against 1,327,634; Abstain 55,473
- · Proposal 3 Ratification of PricewaterhouseCoopers LLC: For 75,870,182; Against 37,685; Abstain 12,913
12-05-2026
Dyadic International, Inc. (DYAI) has issued a proxy statement for its 2026 Virtual Annual Meeting on June 18, 2026, seeking shareholder approval for electing one Class I director for a term ending in 2029, authorizing a discretionary reverse stock split, ratifying Crowe LLP as independent auditors for the year ending December 31, 2026, and an advisory vote on 2025 Named Executive Officer compensation. The record date is April 24, 2026, with 36,438,703 shares of common stock outstanding. Directors and executive officers beneficially own approximately 20.9% of the outstanding common stock.
- · Annual Meeting is virtual only at www.virtualshareholdermeeting.com/DYAI2026, 10:00 a.m. Eastern Daylight Savings Time.
- · Proxy voting deadline: 11:59 p.m. Eastern Daylight Savings Time on June 17, 2026.
- · Board recommends voting FOR all proposals.
12-05-2026
NVIDIA Corporation filed a DEFA14A (definitive additional proxy materials) on May 12, 2026, as Schedule 14A pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing relates to the notice of the 2026 annual meeting and was submitted by the registrant with no fee required. No financial or operational metrics are disclosed in the provided content.
12-05-2026
Advanced Micro Devices Inc (AMD) filed a 13F-HR holdings report as of March 31, 2026, disclosing its equity positions in select companies with no reported changes in share ownership voting authority. The portfolio includes a largest position of 1,151,052 shares in Sanmina Corp valued at $149,222,381, followed by 5,714,285 shares in ABSCI Corporation at $17,142,855, 65,516 shares in Marvell Technology Inc at $6,489,360, and 200,000 shares in Xanadu Quantum Technologies Ltd at $1,532,000. All positions are held solely with no shared or other voting authority.
- · Report filed on May 12, 2026
- · Conformed period end: March 31, 2026
- · All positions report 0 shares with shared or other voting authority
12-05-2026
Cottonwood Communities, Inc. reported total revenues of $47,525 thousand for Q1 2026, up 16.9% YoY from $40,666 thousand, driven by 16.7% growth in rental revenues to $43,553 thousand. However, operating expenses surged 37.7% to $54,722 thousand, primarily due to higher depreciation and amortization, resulting in an operating loss of $7,197 thousand versus $945 thousand income YoY, though net loss narrowed slightly to $12,230 thousand from $13,014 thousand. Total assets decreased to $2,161,682 thousand from $2,190,466 thousand QoQ, reflecting lower real estate assets.
- · Net cash used in operating activities improved to $1,212 thousand from $5,463 thousand YoY.
- · Net cash provided by investing activities $44,341 thousand vs $63,456 thousand YoY.
- · Gain on sale of real estate assets $15,759 thousand in Q1 2026 vs $7,932 thousand YoY.
- · Mortgage notes and revolving credit facility, net decreased to $1,211,623 thousand from $1,246,637 thousand QoQ.
12-05-2026
Genco Shipping & Trading Limited issued a DEFA14A proxy statement ahead of its 2026 Annual Meeting, urging shareholders to vote 'FOR' its highly qualified Board on the WHITE proxy card and 'WITHHOLD' on Diana Shipping Inc.'s nominees amid Diana's hostile takeover campaign. The filing highlights strong Q1 2026 financial performance with net income of $9.3M versus a $11.9M loss in Q1 2025, EBITDA of $34.2M (up 331% YoY), Adjusted EBITDA of $36.2M (up 357% YoY), and TCE rate of $19,346 (up 63% YoY) on a fleet of 44 vessels (up from 42). It refutes Diana's claims, noting Diana's $23.50/share proposal undervalues Genco at below analyst NAV estimates of $26.54 (mean) to $26.80 (median).
- · Genco's Board adopted a limited-duration shareholder rights plan in response to Diana's stock accumulation.
- · Credit agreement includes standard change of control provisions similar to those in Diana's facilities.
- · Fleet utilization improved to 99.2% in Q1 2026 from 98.0% in Q1 2025.
- · Total ownership days: 3,903 in Q1 2026 vs 3,780 in Q1 2025.
12-05-2026
IMUNON reported Q1 2026 net loss of $4.3 million ($0.84 per share) versus $4.1 million ($3.15 per share) in Q1 2025, driven by a 8% increase in R&D expenses to $2.3 million while G&A remained flat at $2.0 million; cash and equivalents declined to $4.8 million from $8.8 million at Dec 31, 2025, with operating cash use rising 43% to $4.0 million. On the clinical front, final Phase 2 OVATION 2 data showed a median 14.7-month OS improvement (45.1 vs. 30.4 months) for IMNN-001 + SoC versus SoC alone in 112 patients, improving from prior 11.1 months, and 24.2 months (65.6 vs. 41.4 months) with added PARP inhibitors. Phase 3 OVATION 3 enrollment is ahead of plan, expected complete Q1 2029, with FDA-aligned BLA path.
- · Strategic reorganization announced Feb 5, 2026 to reduce operating expenses and focus on OVATION 3.
- · First patient dosed in Phase 3 OVATION 3 in Q3 2025.
- · Conference call held May 12, 2026 at 11:00 a.m. ET.
12-05-2026
OptimumBank Holdings, Inc. reported strong Q1 2026 results with total assets growing 14.1% QoQ to $1,268.7M, driven by 13.8% loan growth to $1,078.5M and 17.3% deposit growth to $1,092.9M; net interest income surged 39.9% YoY to $13.2M, boosting net income 20.5% YoY to $4.7M (basic EPS $0.39 vs $0.33). However, noninterest expenses rose 42.2% YoY to $8.0M due to higher salaries and data processing costs, and the company recorded a $0.8M credit loss provision versus a $0.2M reversal in Q1 2025.
- · Allowance for credit losses increased to $11,061k from $10,273k QoQ.
- · Stockholders’ equity grew 4.0% QoQ to $126,848k.
- · Net cash used in investing activities $133,537k due to $131,943k net increase in loans.
- · Other comprehensive loss of $134k in Q1 2026 vs income of $417k in Q1 2025.
12-05-2026
Ilmarinen Mutual Pension Insurance Co disclosed 462 equity holdings totaling $12,713,221,000 as of March 31, 2026, in its 13F-HR filing submitted on May 12, 2026. Top positions by value include XTRACKERS MSCI USA CLIMATE ACTION EQUITY ETF ($2.06B), Apple Inc. ($478.8M), Alphabet Inc. Class A ($395.2M), Amazon.com Inc. ($272.0M), and Broadcom Inc. ($169.7M). All holdings are reported as sole discretionary.
- · Report period end date: March 31, 2026
- · Filing date: May 12, 2026
- · All positions held solely on discretionary basis with zero shared or other management
12-05-2026
Murphy USA Inc. announced a private offering of $500 million aggregate principal amount of senior notes due 2034 by its wholly owned subsidiary, Murphy Oil USA, Inc., guaranteed on a senior unsecured basis by Murphy USA and certain domestic subsidiaries. The company intends to use net proceeds to redeem all $300,000,000 of the issuer's existing 5.625% senior notes due 2027, repay outstanding borrowings under its revolving credit facility, pay related fees and expenses, and for general corporate purposes if proceeds remain. The notes will be offered only to qualified institutional buyers under Rule 144A and certain non-U.S. persons under Regulation S, and are not registered under the Securities Act.
- · The company intends to issue a notice of full redemption for the 2027 Notes upon pricing of the Offering, with redemption price per the indenture plus accrued interest.
- · No assurances that the redemption of the 2027 Notes will be completed.
- · Notes are senior unsecured and not registered under the Securities Act.
12-05-2026
JPMorgan Chase & Co. filed a Schedule 13G/A amendment on May 12, 2026, reporting beneficial ownership of 13,547,554 shares (9.2%) of Warner Music Group Corp.'s Class A Common Stock as of March 31, 2026. Ownership is aggregated across JPMorgan entities and held in the ordinary course of business, not for the purpose of influencing control. No material changes in ownership levels are indicated in the filing.
- · Filed under Rule 13d-1(b) as a passive investor
- · Warner Music Group Corp. address: 1633 Broadway, New York, NY 10019
- · JPMorgan Chase & Co. address: 270 Park Avenue, New York, NY 10017
12-05-2026
Leading Edge Financial Planning LLC filed its 13F-HR report on May 12, 2026, disclosing 72 sole discretionary equity holdings as of March 31, 2026. Top positions by market value include SPDR Series Trust (CUSIP 78464A854) at $70,011,329, Dimensional ETF Trust International Core Equity Market ETF (CUSIP 25434V799) at $69,516,527, and Dimensional ETF Trust US High Profitability ETF (CUSIP 25434V831) at $44,114,675. Other significant holdings feature Schwab Strategic Trust US Broad Market ETF ($41,186,154) and Dimensional ETF Trust US Small Cap Value ETF ($33,963,461).
- · All 72 positions held as sole discretionary with 0 shared, 0 other manager voting authority.
- · Filer address: 6921 Office Park Circle, Knoxville, TN 37909.
- · Report period end: March 31, 2026.
- · Notable individual stock holdings: Apple Inc (3,297 shares, $836,623), NVIDIA Corporation (1,503 shares, $262,157), Amazon.com Inc (1,950 shares, $406,126).
12-05-2026
Muncy Columbia Financial Corporation issued a press release on May 12, 2026, declaring a dividend and authorizing a new treasury stock repurchase program, as disclosed in this Form 8-K under Item 8.01 Other Events. The press release is attached as Exhibit 99.1. No specific amounts or details on the dividend or repurchase program were provided in the filing body.
- · Filing includes Exhibit 99.1: Press Release dated May 12, 2026.
- · Securities registered pursuant to Section 12(b): None.
12-05-2026
Octave Intelligence Public Limited Company filed an 8-K on May 12, 2026 (Items 5.03, 8.01, 9.01), attaching Exhibit 3.1: the amended Memorandum of Association (Cert. No. 607457) under Companies Act 2014, updated through resolutions up to April 27, 2026. The document broadly expands the company's objects to include holding company operations, manufacturing, distribution, investment, borrowing/lending, financial transactions, property development, and forming subsidiaries or joint ventures. No financial metrics or performance data are disclosed.
- · Registered under Part 17 of the Companies Act 2014
12-05-2026
Paradigm Asset Management Co LLC filed its 13F-HR on May 12, 2026, disclosing equity holdings as of March 31, 2026, across approximately 400 positions primarily in U.S. and international large-cap stocks. Top holdings by market value include Alphabet Inc. CL A (9233552 USD), JPMorgan Chase & Co. (8645657 USD), Apple Inc. (5112853 USD), ASML Holding NV (4730040 USD), and Alphabet Inc. CL C (1328162 USD). The portfolio shows diversified exposure with many positions held solely (discretionary) and others managed on behalf of clients.
- · Report period end date: 2026-03-31
- · Filing date: 2026-05-12
- · Holdings include a mix of sole discretionary shares and other managed shares across sectors like technology, financials, and healthcare
12-05-2026
Community Bank, N.A. filed its 13F-HR report on May 12, 2026, disclosing equity holdings as of March 31, 2026, across 698 securities with a total market value of $840109213. Top holdings include Apple Inc. at $93628149 (368920 shares), Alphabet Inc. Class A at $11176140 (38867 shares), Amazon.com Inc. at $8004355 (38433 shares), Exxon Mobil Corp. at $8709977 (51338 shares), and Cisco Systems Inc. at $9784893 (126111 shares). The portfolio shows diversification into ETFs like Avantis US Smallcap Value ETF ($6312354, 57141 shares) and sectors including technology, energy, healthcare, and utilities, with positions held as sole or defined discretionary.
- · Holdings include both SOLE and DFND discretionary positions
- · Business address: 5790 Widewaters Parkway, DeWitt, NY 13214
12-05-2026
Azimuth Capital Investment Management LLC disclosed total equity holdings of $2,657,468,303 across 300 positions in its 13F-HR filing as of March 31, 2026. Top holdings include Apple Inc. ($115,434,077), NVIDIA Corp. ($101,801,853), Microsoft Corp. ($89,894,149), and Broadcom Inc. ($77,947,308), reflecting a focus on large-cap technology stocks. No prior period comparisons are available in this filing.
- · Filing date: May 12, 2026
- · Report period end date: March 31, 2026
- · Filer CIK: 0001942364
- · Business address: 200 E. LONG LAKE ROAD SUITE 160, BLOOMFIELD HILLS, MI 48304
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 40 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Nasdaq 100 Stocks SEC Filings
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals